Shanghai Pharmaceuticals Holding (SHA:601607, HKG:2607) received approval to market its aripiprazole tablets in the Philippines after obtaining a drug registration certificate, according to a Saturday filing on the Shanghai bourse.
The Chinese pharmaceutical company's Shanghai shares rose less than 1% during Monday's midday trade.
The drug is mainly used to treat schizophrenia and manic episodes of bipolar disorder. The antipsychotic drug can also be used as adjunctive therapy for depression.